Testing an immune-boosting TB vaccine in people with or without HIV
Part of Infections clinical trials.
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 12 to 55 when you enroll
- Have a participating study site/clinic follow you for the whole study
- Be able to give consent (or have a parent/guardian for ages under 18, plus your written “assent” when required)
- Have had BCG vaccine only in infancy (not later)
- Be willing to share your HIV test results and participate in HIV prevention counseling if you don’t have HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether MTBVAC can safely protect newborn babies from tuberculosis and whether it helps the baby’s immune system learn to fight TB. If you enroll, the goal is to see safety and immune response in real newborn settings in sub-Saharan Africa.
This trial tests an experimental vaccine called VIR-1778 that may help protect against infections caused by two viruses: cytomegalovirus (CMV) and tuberculosis (TB). The study looks at whether the vaccine is safe and how well it works in healthy adults.
This study tests a daily combination of two medicines, rifapentine and isoniazid, to prevent tuberculosis (TB) in children under 13 years old. It aims to see if this short treatment is safe and works well for kids, including those living with HIV.
This study measures how strongly your immune system responds to COVID-19 vaccines. It includes people with newly diagnosed tuberculosis and a healthier comparison group, aiming to understand vaccine immune effects and safety.
This early-phase trial tests a new vaccine designed to prevent tuberculosis (TB). It helps researchers see if the vaccine is safe and produces an immune response in healthy adults. Participation may contribute to the development of a new prevention tool for TB.
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.